Abstract: A method of controlling an operation of a display device using eye movements and a device for performing the method are provided. The method includes receiving eye movement information of a user; receiving blinking information of the user; generating a control command corresponding to the eye movement information and the blinking information; and controlling an operation of the display device based on the generated control command.

Abstract: The present disclosure provides a compound represented by Formula (I) and a pharmaceutically acceptable salt which are effective as a dopamine reuptake inhibitor and a method of using the compound: wherein X is independently halo, alkyl, alkoxy or nitro; m is 0, 1, 2, 3 or 4; n is 1 or 2; R1 and R2 are independently H— or alkyl; R3 is H—, alkyl or aralkyl; and R4 is H— or aryl.

Abstract: A method of controlling an operation of a display device using eye movements and a device for performing the method are provided. The method includes receiving eye movement information of a user; receiving blinking information of the user; generating a control command corresponding to the eye movement information and the blinking information; and controlling an operation of the display device based on the generated control command.

Abstract: The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.

Abstract: The present disclosure provides a compound represented by Formula (I) and a pharmaceutically acceptable salt which are effective as a dopamine reuptake inhibitor and a method of using the compound: wherein X is independently halo, alkyl, alkoxy or nitro; m is 0, 1, 2, 3 or 4; n is 1 or 2; R1 and R2 are independently H— or alkyl; R3 is H—, alkyl or aralkyl; and R4 is H— or aryl.

Abstract: The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.

Abstract: A method and electronic device for receiving information is provided. The method includes transmitting, by the electronic device, a scan time and an identification of the information to cause the identified information to be broadcast at the scan time; and scanning, by the electronic device, during the scan time to receive the information. The electronic device includes a transmitter configured to transmit a scan time and an identification of the information to cause the identified information to be broadcast at the scan time; and a scanner configured to scan during the scan time to receive the information.

Abstract: A method and display apparatus for providing content are provided. The method for providing content includes displaying a content UI in which a plurality of content is included, detecting an area at which a user gazes in the content UI, determining a preference for gaze content that is present in the area at which the user gazes by measuring user's brainwaves, and providing the content UI based on the determined preference. The user can be provided with the content UI that is configured more intuitively and conveniently according to the user preference.

Abstract: A method and display apparatus for providing content are provided. The method for providing content includes displaying a content UI in which a plurality of content is included, detecting an area at which a user gazes in the content UI, determining a preference for gaze content that is present in the area at which the user gazes by measuring user's brainwaves, and providing the content UI based on the determined preference. The user can be provided with the content UI that is configured more intuitively and conveniently according to the user preference.

Abstract: The present disclosure provides a compound represented by Formula (I) and a pharmaceutically acceptable salt which are effective as a dopamine reuptake inhibitor and a method of using the compound: wherein X is independently halo, alkyl, alkoxy or nitro; m is 0, 1, 2, 3 or 4; n is 1 or 2; R1 and R2 are independently H— or alkyl; R3 is H—, alkyl or aralkyl; and R4 is H— or aryl.

Abstract: The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.

Abstract: A method of controlling a device by an eye action is provided. The method includes selecting a controller to execute a control command generated by the eye action of a user, obtaining data about the eye action of the user, detecting the control command corresponding to the eye action of the user based on the obtained data, and executing the detected control command by using the selected controller.

Abstract: The present disclosure provides a compound represented by Formula (I) and a pharmaceutically acceptable salt which are effective as a dopamine reuptake inhibitor and a method of using the compound: wherein X is independently halo, alkyl, alkoxy or nitro; m is 0, 1, 2, 3 or 4; n is 1 or 2; R1 and R2 are independently H— or alkyl; R3 is H—, alkyl or aralkyl; and R4 is H— or aryl.

Abstract: An apparatus and a method are provided for receiving a signal in a communication system supporting a Gaussian frequency shift keying (GFSK) modulation scheme. The method includes receiving the signal; and estimating a codeword vector by performing a signal detecting operation based on a GFSK-maximum likelihood sequence estimation (MLSE) scheme, which is based on a GFSK modulation scheme and an MLSE scheme, on the received signal. States of a Viterbi trellis that are used in the GFSK-MLSE scheme are determined based on the GFSK modulation scheme.

Abstract: Provided is a pharmaceutical composition for inhibiting apoptosis of neurons or neurodegeneration. The pharmaceutical composition effectively prevents or treats diseases related to apoptosis of neurons or neurodegeneration.

Abstract: A method and electronic device for receiving information is provided. The method includes transmitting, by the electronic device, a scan time and an identification of the information to cause the identified information to be broadcast at the scan time; and scanning, by the electronic device, during the scan time to receive the information. The electronic device includes a transmitter configured to transmit a scan time and an identification of the information to cause the identified information to be broadcast at the scan time; and a scanner configured to scan during the scan time to receive the information.

Abstract: An apparatus and a method are provided for receiving a signal in a communication system supporting a Gaussian frequency shift keying (GFSK) modulation scheme. The method includes receiving the signal; and estimating a codeword vector by performing a signal detecting operation based on a GFSK-maximum likelihood sequence estimation (MLSE) scheme, which is based on a GFSK modulation scheme and an MLSE scheme, on the received signal. States of a Viterbi trellis that are used in the GFSK-MLSE scheme are determined based on the GFSK modulation scheme.

Abstract: A proximity estimation method and apparatus are provided for measuring a distance between devices in a wireless communication system. The method includes transmitting, by a first device, a first signal to a second device; receiving, by the first device, a second signal from the second device, in response to the first signal; and measuring, by the first device, a distance between the first device and the second device, based on a phase difference between the first signal and the second signal.

Abstract: The present disclosure provides a compound represented by Formula (I) and a pharmaceutically acceptable salt which are effective as a dopamine reuptake inhibitor and a method of using the compound: wherein X is independently halo, alkyl, alkoxy or nitro; m is 0, 1, 2, 3 or 4; n is 1 or 2; R1 and R2 are independently H— or alkyl; R3 is H—, alkyl or aralkyl; and R4 is H— or aryl.

Abstract: A method of controlling an operation of a display device using eye movements and a device for performing the method are provided. The method includes receiving eye movement information of a user; receiving blinking information of the user; generating a control command corresponding to the eye movement information and the blinking information; and controlling an operation of the display device based on the generated control command.